This paper provides a vision describing how Gen AI technologies will reshape the possibilities and practice of Medical Affairs related to the four functional pillars of Strategy & Leadership, Evidence & Insights Generation, Evidence & Insights Communication, and Engagement & Partnerships.
The Medical community knows it needs to improve equity in clinical trials, but what really helps when it comes to changing patient and provider perceptions? PlatformQ Health is pleased to share insights into strategies for helping patients become more receptive to trial participation and supporting providers in fostering inclusion.
While the value of patient engagement is increasingly recognised in the clinical and launch phases of drug development, it is still a relatively new concept to involve patients in the early discovery phase. By understanding the burden of disease and patient’s aspirations for new treatments from the outset, pharma companies can ensure they are developing medicines that matter to patients. As experts in the disease area and therapeutic landscape, Medical Affairs are well placed to initiate and develop effective patient partnerships to ensure that the patient voice is incorporated during early discovery and beyond.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
This webinar will discuss how MA colleagues are best positioned to explore the fusion of PE and PED in the post-launch phase, including generation and use of RWD and RW evidence, and will share guidance and information on several industry-supported resources, to enable MA colleagues to implement PE and evidence strategies in their function. Importantly, patient and patient advocate perspectives will also be considered, sharing opportunities, and best practice examples of how MA colleagues can overcome perceived barriers, to achieve true and impactful PE.
Following the presentation, participants will have a greater understanding of:
- Current best practice in patient engagement, from both an industry, patient advocate and patient perspective
- The convergence of patient experience data, real world evidence and patient engagement activity and why this is important to Medical Affairs
- What patients and their advocates need from their industry partners for better patient engagement and how this is likely to evolve
- The specific impact patient engagement can have on a Medical Affairs strategy and the various research, tools and guidance available to support this
MAPS speaks with Annemarie Clegg, CMO, OPEN Health, about the evolving role of Medical Affairs in providing context for payers, regulators and policy makers whose decisions can dramatically affect which patients can access industry innovations.
This webinar will be covering:
1. Looking into the future of MA in Japan
a. How to engage more with Patients/Patient Advocacy groups
b. How to bring more value to customers, scientific leaders and health systems
c. How to better engage academia and health authority group through scientific exchange
2. Opportunities for improving effectiveness
a. Differentiation of MSL and Medical Rep roles- how are companies differentiating despite the regulations?
At the MAPS 2022 Global Annual Meeting, we sat down with Riad Dirani, Vice President of Global Health Economics and Outcomes Research at Teva Pharmaceuticals, and Omar Dabbous, Vice President of Global Health Economics and Outcomes Research and Real World Evidence at AveXis to chat about the structure and activities of HEOR within Medical Affairs.